Todd Zavodnick

Revance Appoints New President of Aesthetics and Therapeutics

Revances appoints new CCO of Aesthetics

Revance Therapeutics, a biotechnology company developing botulinum toxin products for aesthetic and therapeutic concerns has appointed Todd Zavodnick to chief commercial officer and president of its Aesthetics & Therapeutics division. Zavodnick will report to Revance’s CEO Dan Browne, and lead the company’s commercial operations along with the launch of its injectable daxibotulinumtoxinA (RT002).